NCT00451386

Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)

A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Local Tolerability, and Clinical Outcome of Ertapenem Versus Ceftriaxone in Pediatric Patients With Complicated Urinary Tract Infection, Skin and Soft Tissue Infection, or Community-Acquired Pneumonia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 400 (planned)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 3 Months – 17 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate the safety and efficacy of ertapenem versus ceftriaxone in pediatric patients with urinary tract infections, skin infections, or community-acquired pneumonia.

Conditions

• Urinary Tract Infections
• Bacterial Pneumonia
• Soft Tissue Infections

Interventions

Type	Name	Description
DRUG	MK0826, ertapenem sodium /Duration of Treatment: 14 Days
DRUG	Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days

Timeline

• Start date: 2002-01-01
• Primary completion: 2003-12-01
• Completion: 2003-12-01
• First posted: 2007-03-23
• Last updated: 2017-02-17